9
Views
22
CrossRef citations to date
0
Altmetric
Original Articles

Ambient Monitoring of Cyclophosphamide in Manufacture and Hospitals

, &
Pages 314-317 | Published online: 04 Jun 2010
 

Abstract

Cyclophosphamide (CP), one of the most commonly used cytostatic drugs, is known to be a human carcinogen. In this study, CP represents a model compound for the identification of potential exposure situations in the various phases of its manufacture and hospital use. Ambient air samples were taken in the various phases and analyzed for CP. A low detection limit (0.05 µg/m3 for a 1 m3 sample volume) was obtained for CP using the mass spectrometry method (MS) developed for this study. The detection limit was 1 µg/m3 with the high performance liquid chromatography (HPLC) method. The correlation between the two methods was good. The highest potential exposure situations were found to occur during specific operations at the end of the process. During these operations the airborne CP concentrations may rise as high as several hundred µg/m3, and the workers must use supplied-air respirators, gloves and protective clothing. For the measurements in hospital use, air samples were taken from flow hoods. During normal working practices, no measurable amounts of CP could be observed. A filter from a flow hood, however, contained CP in measurable quantities, showing that occasional spilling may occur.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.